RU2006143758A - BY THE EXISTENCE PURE 2 - {[2- (2-METHYLAMINOPYRIMIDIN-4-IL) -1H-INDOL-5-CARBONIL] -AMINO} -3- (Phenylpyridin-2-ILAMINO) PROPIONIC ACID IN CASIUM - Google Patents

BY THE EXISTENCE PURE 2 - {[2- (2-METHYLAMINOPYRIMIDIN-4-IL) -1H-INDOL-5-CARBONIL] -AMINO} -3- (Phenylpyridin-2-ILAMINO) PROPIONIC ACID IN CASIUM Download PDF

Info

Publication number
RU2006143758A
RU2006143758A RU2006143758/04A RU2006143758A RU2006143758A RU 2006143758 A RU2006143758 A RU 2006143758A RU 2006143758/04 A RU2006143758/04 A RU 2006143758/04A RU 2006143758 A RU2006143758 A RU 2006143758A RU 2006143758 A RU2006143758 A RU 2006143758A
Authority
RU
Russia
Prior art keywords
effective amount
patient
agonist
administering
pharmaceutically effective
Prior art date
Application number
RU2006143758/04A
Other languages
Russian (ru)
Inventor
Эль-Бдауи АДДАД (US)
Эль-Бдауи Аддад
Олаф РИТЦЕЛЕР (DE)
Олаф Ритцелер
Дэвид Дж. ОЛДОУС (US)
Дэвид Дж. ОЛДОУС
Пол Джозеф КОКС (US)
Пол Джозеф Кокс
Original Assignee
Авентис Фармасьютикалз Инк. (Us)
Авентис Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фармасьютикалз Инк. (Us), Авентис Фармасьютикалз Инк. filed Critical Авентис Фармасьютикалз Инк. (Us)
Publication of RU2006143758A publication Critical patent/RU2006143758A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (14)

1. По существу чистое соединение формулы (A)1. Essentially pure compound of the formula (A)
Figure 00000001
Figure 00000001
 или его фармацевтически приемлемая соль или сольват.or a pharmaceutically acceptable salt or solvate thereof. 2. Фармацевтическая композиция, содержащая фармацевтически эффективное количество соединения формулы (A) и фармацевтически приемлемый носитель.2. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of formula (A) and a pharmaceutically acceptable carrier. 3. Способ лечения пациента, страдающего патологическим состоянием или подверженному патологическим состоянием, которое может быть облегчено ингибированием IKK-2 путем введения указанному пациенту фармацевтически эффективного количества соединения по п.1.3. A method of treating a patient suffering from a pathological condition or susceptible to a pathological condition that can be alleviated by inhibiting IKK-2 by administering to said patient a pharmaceutically effective amount of a compound according to claim 1. 4. Способ по п.3, где введение проводят с получением локализованного действия.4. The method according to claim 3, where the introduction is carried out with obtaining a localized action. 5. Способ по п.3, где патологическим состоянием является астма, ринит, хроническое обструктивное заболевание легких или обострения хронического обструктивного заболевания легких.5. The method according to claim 3, where the pathological condition is asthma, rhinitis, chronic obstructive pulmonary disease or exacerbation of chronic obstructive pulmonary disease. 6. Способ по п.3, где введение проводят интратрахеально, интраназально, ингаляционно или при помощи аэрозоля.6. The method according to claim 3, where the introduction is carried out intratracheally, intranasally, inhalation or by aerosol. 7. Способ лечения пациента, страдающего от астмы, включающий введение пациенту фармацевтически эффективного количества соединения по п.1.7. A method of treating a patient suffering from asthma, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1. 8. Способ лечения пациента, страдающего от ринита, включающий введение пациенту фармацевтически эффективного количества соединения по п.1.8. A method of treating a patient suffering from rhinitis, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1. 9. Способ лечения пациента, страдающего от хронического обструктивного заболевания легких, включающий введение пациенту фармацевтически эффективного количества соединения по п.1.9. A method of treating a patient suffering from chronic obstructive pulmonary disease, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1. 10. Способ лечения пациента, страдающего от обострений хронического обструктивного заболевания легких, включающий введение пациенту фармацевтически эффективного количества соединения по п.1.10. A method of treating a patient suffering from exacerbations of chronic obstructive pulmonary disease, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1. 11. Фармацевтическая композиция по п.2, дополнительно содержащая фармацевтически эффективное количество соединения, выбранное из группы, включающей бронходилатор, бета 2-агонист длительного действия, антихолинергические средства, метилксантин и противовоспалительное средство, в смеси с фармацевтически приемлемым носителем.11. The pharmaceutical composition according to claim 2, further comprising a pharmaceutically effective amount of a compound selected from the group consisting of a bronchodilator, long-acting beta 2 agonist, anticholinergics, methylxanthine and an anti-inflammatory agent, in admixture with a pharmaceutically acceptable carrier. 12. Фармацевтическая композиция по п.11, в котором бронходилатором является бета 2-агонист кратковременного действия; бета 2-агонистом длительного действия может быть салметерол или формотерол; антихолинергическим средством может быть бромид ипратропия и бромид тиотропия; метилксантином является теофиллин; противовоспалительным средством могут быть ингибиторы рекрутинга клеток и медиаторы токсического воспаления, ингибиторы протеолитических ферментов, антиоксиданты, ингибиторы выделения слизи и антибиотики.12. The pharmaceutical composition according to claim 11, in which the bronchodilator is a short-acting beta 2-agonist; long-acting beta 2-agonist may be salmeterol or formoterol; the anticholinergic agent may be ipratropium bromide and tiotropium bromide; methylxanthine is theophylline; anti-inflammatory agents can be cell recruitment inhibitors and toxic inflammation mediators, proteolytic enzyme inhibitors, antioxidants, mucus secretion inhibitors and antibiotics. 13. Способ лечения по п.3, дополнительно включающий введение фармакологически эффективного количества соединения, выбранное из группы, включающей бронходилатор, бета-2 агонист длительного действия, антихолинергические средства, метилксантин и противовоспалительное средство, в смеси с фармацевтически приемлемым носителем.13. The treatment method according to claim 3, further comprising administering a pharmacologically effective amount of a compound selected from the group consisting of a bronchodilator, long-acting beta-2 agonist, anticholinergics, methylxanthine and an anti-inflammatory agent, in admixture with a pharmaceutically acceptable carrier. 14. Способ лечения по п.13, в котором бронходилатором является бета 2-агонист кратковременного действия; бета 2-агонистом длительного действия может быть салметерол или формотерол; антихолинергическим средством может быть бромид ипратропия и бромид тиотропия; метилксантином является теофиллин; противовоспалительным средством могут быть ингибиторы рекрутинга клеток и медиаторы токсического воспаления, ингибиторы протеолитических ферментов, антиоксиданты, ингибиторы выделения слизи и антибиотики.14. The treatment method according to item 13, in which the bronchodilator is a short-acting beta 2-agonist; long-acting beta 2-agonist may be salmeterol or formoterol; the anticholinergic agent may be ipratropium bromide and tiotropium bromide; methylxanthine is theophylline; anti-inflammatory agents can be cell recruitment inhibitors and toxic inflammation mediators, proteolytic enzyme inhibitors, antioxidants, mucus secretion inhibitors and antibiotics.
RU2006143758/04A 2004-05-12 2005-05-11 BY THE EXISTENCE PURE 2 - {[2- (2-METHYLAMINOPYRIMIDIN-4-IL) -1H-INDOL-5-CARBONIL] -AMINO} -3- (Phenylpyridin-2-ILAMINO) PROPIONIC ACID IN CASIUM RU2006143758A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12
US60/570,146 2004-05-12

Publications (1)

Publication Number Publication Date
RU2006143758A true RU2006143758A (en) 2008-06-27

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006143758/04A RU2006143758A (en) 2004-05-12 2005-05-11 BY THE EXISTENCE PURE 2 - {[2- (2-METHYLAMINOPYRIMIDIN-4-IL) -1H-INDOL-5-CARBONIL] -AMINO} -3- (Phenylpyridin-2-ILAMINO) PROPIONIC ACID IN CASIUM

Country Status (23)

Country Link
EP (1) EP1747215A1 (en)
JP (1) JP2007537266A (en)
KR (1) KR20070011483A (en)
CN (1) CN1950359A (en)
AR (1) AR049274A1 (en)
AU (1) AU2005245834A1 (en)
BR (1) BRPI0511029A (en)
CA (1) CA2566213A1 (en)
EC (1) ECSP066992A (en)
GT (1) GT200500111A (en)
IL (1) IL178992A0 (en)
MA (1) MA28553B1 (en)
MX (1) MXPA06012870A (en)
NO (1) NO20065719L (en)
PA (1) PA8633101A1 (en)
PE (1) PE20060269A1 (en)
RU (1) RU2006143758A (en)
SV (1) SV2006002111A (en)
TN (1) TNSN06338A1 (en)
TW (1) TW200605881A (en)
UY (1) UY28897A1 (en)
WO (1) WO2005113544A1 (en)
ZA (1) ZA200608712B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (en) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
DE102004033406A1 (en) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Process for the preparation of the enantiomeric forms of 2,3-diaminopropionic acid derivatives
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
JP5634596B2 (en) * 2010-04-27 2014-12-03 ハチソン メディファーマ リミテッド Pyrimidinylindole compounds
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
CN106588803A (en) * 2016-11-16 2017-04-26 西南科技大学 Novel method for preparing 5-acetylisoxazole

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase

Also Published As

Publication number Publication date
PE20060269A1 (en) 2006-05-11
SV2006002111A (en) 2006-01-30
ECSP066992A (en) 2006-12-29
ZA200608712B (en) 2008-06-25
NO20065719L (en) 2006-12-12
PA8633101A1 (en) 2006-01-23
CA2566213A1 (en) 2005-12-11
GT200500111A (en) 2006-05-09
MXPA06012870A (en) 2007-02-15
TNSN06338A1 (en) 2008-02-22
EP1747215A1 (en) 2007-01-31
AR049274A1 (en) 2006-07-12
IL178992A0 (en) 2007-03-08
AU2005245834A1 (en) 2005-12-01
MA28553B1 (en) 2007-04-03
TW200605881A (en) 2006-02-16
BRPI0511029A (en) 2007-11-27
JP2007537266A (en) 2007-12-20
KR20070011483A (en) 2007-01-24
UY28897A1 (en) 2005-12-30
CN1950359A (en) 2007-04-18
WO2005113544A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
RU2006143758A (en) BY THE EXISTENCE PURE 2 - {[2- (2-METHYLAMINOPYRIMIDIN-4-IL) -1H-INDOL-5-CARBONIL] -AMINO} -3- (Phenylpyridin-2-ILAMINO) PROPIONIC ACID IN CASIUM
US7008951B2 (en) Mixtures or organic compounds for the treatment of airway diseases
ES2320994T3 (en) DERIVATIVES OF QUINOLINA-2-ONA FOR THE TREATMENT OF DISEASES OF RESPIRATORY ROADS.
ES2331879T3 (en) DERIVATIVES OF BENZOTIAZOL THAT HAVE AGONIST ACTIVITY OF THE BETA-2 ADRENORECEPTOR.
US8088935B2 (en) Compounds and methods for the treatment of asthma
EP1957451B1 (en) Soft anticholinergic zwitterions
KR100950870B1 (en) Anticholinergic agents, method for producing the same and use thereof as medicaments
US20070208060A1 (en) Compounds for treating inflammatory diseases
RU2006137717A (en) [4 - (- AMINOMETHYL-2-fluorophenyl) -PEPERIDIN-1-IL] - (4-BROM-3-METHID-5-PROXYTHIOPHEN-2-IL) -METHANONE HYDROCHLORIDE AS A MASCULAR TRIPTASE INHIBITOR
WO2005110402A1 (en) Combinations of glycopyrrolate and beta2 adrenoceptor agonists
JP2009046490A (en) Aerosol composition containing formoterol for delivery to lungs via nebulization
KR20060127974A (en) Combination of benzothiazol-2-one beta2 adrenoceptor agonists and corticosteroids for the treatment of respiratory diseases
TW200303767A (en) Formoterol superfine formulation
KR20080068085A (en) Treatment of asthma and copd using triple-combination therapy
KR20080069196A (en) Organic compounds comprising a glycopyrronium salt
KR20180028563A (en) Pharmaceutical composition
CN101883562A (en) Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti-inflammatory and the use thereof for the treatment of respiratory disorders
US20060270667A1 (en) Novel medicament combinations for the treatment of respiratory diseases
JP2022520990A (en) How to treat respiratory illness
JP4104984B2 (en) Novel benzamidine derivatives with anti-inflammatory and immunosuppressive activity
US9040588B2 (en) Acetamide stereoisomer
US20090238770A1 (en) Organic compounds
Balzano et al. Leukotriene receptor antagonists in the treatment of asthma: an update
AU2011311310A1 (en) Novel combinations
US8173829B2 (en) Carbamate stereoisomer

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090302

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090302